{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:45:45Z","timestamp":1786653945273,"version":"build-2736575974"},"reference-count":76,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"8","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      In oncology, interpreting clinical trials solely through statistical significance (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .05) often conflates true biological futility with methodological false negatives. This binary oversimplification risks prematurely abandoning active therapies while wasting resources on futile programs. We aimed to develop a structured framework to evaluate late-phase trials beyond simple\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value assessments. Through a critical review of literature and landmark late-phase oncology trials, we analyzed common failure mechanisms and methodological pitfalls to construct a comprehensive, three-step methodology for the post hoc evaluation of negative studies. The review yielded a synthesized framework that approaches trial interpretation through three sequential steps. First, classification stratifies trials into five distinct categories: true negatives, false negatives, inconclusive trials, positive but irrelevant results, and nonsuperior but clinically valuable. Second, diagnosis uses root-cause analysis to identify underlying trial design flaws, execution biases, or statistical pitfalls. Third, recommendations outline targeted actionable strategies, including trial redesign, supplementary biomarker validation, precision medicine approaches, or scientific confirmation of therapeutic futility. This framework shifts trial interpretation from a simple win\/loss assessment to a nuanced, value-based strategy. By systematically dissecting the root causes of trial failures, it empowers researchers to rescue therapies with latent clinical benefit or confidently confirm futility, thereby optimizing the evidence landscape for precision oncology.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/po-26-00271","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:00:12Z","timestamp":1786651212000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Beyond the\n                    <i>P<\/i>\n                    Value: A Systematic Framework for Interpreting Oncology Clinical Trials"],"prefix":"10.1200","volume":"10","author":[{"given":"Ruyue","family":"Li","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujing","family":"Yao","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, Weifang Medical University, Weifang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"An","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, Weifang Medical University, Weifang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4665-8900","authenticated-orcid":true,"given":"Yintao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02160-z"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1301"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32635"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad145"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01937-w"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.21022"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.09.023"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-13851-4"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12902"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12540"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42400-5"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613493"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03579"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00036"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01658-0"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02574-0"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00533"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.1483"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00469-2"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02747"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.2666"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502931"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00004-8"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03642-9"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00326-6"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00692-6"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00382-0"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00774-2"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01366-1"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00515-6"},{"key":"e_1_3_6_33_2","first-page":"203","article-title":"Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trial","volume":"75","author":"Tang LL","year":"2025","unstructured":"Tang LL, Chen L, Xu GQ, et al: Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trial. CA Cancer J Clin 75:203-215, 2025","journal-title":"CA Cancer J Clin"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00027-0"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30241-9"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30078-9"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810699"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30673-9"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.009"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03658-y"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.07.006"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202102500"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.0147"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01989"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-022-00401-4"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.1910"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.11.039"},{"key":"e_1_3_6_48_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2394"},{"key":"e_1_3_6_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.12.010"},{"key":"e_1_3_6_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615"},{"key":"e_1_3_6_51_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.8009"},{"key":"e_1_3_6_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30754-3"},{"key":"e_1_3_6_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32531-9"},{"key":"e_1_3_6_54_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549"},{"key":"e_1_3_6_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/2056-4538.12371"},{"key":"e_1_3_6_56_2","doi-asserted-by":"crossref","first-page":"e076316","DOI":"10.1136\/bmj-2023-076316","article-title":"The estimands framework: A primer on the ICH E9(R1) addendum","volume":"384","author":"Kahan BC","year":"2024","unstructured":"Kahan BC, Hindley J, Edwards M, et al: The estimands framework: A primer on the ICH E9(R1) addendum. BMJ 384:e076316, 2024","journal-title":"BMJ"},{"key":"e_1_3_6_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.09.010"},{"key":"e_1_3_6_58_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000322"},{"key":"e_1_3_6_59_2","volume-title":"NICE DSU Technical Support Document 16: Adjusting Survival Time Estimates in the Presence of Treatment Switching","author":"Latimer NR","year":"2014","unstructured":"Latimer NR, Abrams KR: NICE DSU Technical Support Document 16: Adjusting Survival Time Estimates in the Presence of Treatment Switching. London, National Institute for Health and Care Excellence (NICE), 2014"},{"key":"e_1_3_6_60_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-016-0472-3"},{"key":"e_1_3_6_61_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002873"},{"key":"e_1_3_6_62_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022485"},{"key":"e_1_3_6_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00221-0"},{"key":"e_1_3_6_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101591"},{"key":"e_1_3_6_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00086-8"},{"key":"e_1_3_6_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30689-8"},{"key":"e_1_3_6_67_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308345"},{"key":"e_1_3_6_68_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.5005"},{"key":"e_1_3_6_69_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01829-9"},{"key":"e_1_3_6_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinsp.2024.100426"},{"key":"e_1_3_6_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30274-8"},{"key":"e_1_3_6_72_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7189"},{"key":"e_1_3_6_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00198-9"},{"key":"e_1_3_6_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00559-6"},{"key":"e_1_3_6_75_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01800"},{"key":"e_1_3_6_76_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1916477"},{"key":"e_1_3_6_77_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103294"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-26-00271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:00:14Z","timestamp":1786651214000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-26-00271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":76,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1200\/PO-26-00271"],"URL":"https:\/\/doi.org\/10.1200\/po-26-00271","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2026-03-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2600271"}}